The top list of clinical trial applicants is Zhengda Tianqing and Hengrui

In October, 59 clinical trials of be were registered, 27 of which were consistency evaluation trials; The hottest registered varieties in October were rivaroxaban tablets and pantoprazole sodium enteric coated tablets; In October, the most concerned bidding unit was Zhengda Tianqing Pharmaceutical Group Co., Ltd In October 2019, a total of 188 drug clinical trials (11.24% month-on-month increase) were publicly registered in CDE, including 139 chemical drugs (59 chemical be clinical trials, 80 chemical clinical applications), 37 biological products and 12 traditional Chinese medicine / natural drugs In October 2019, among the drug clinical registration varieties publicized by CDE, rivaroxaban tablets and pantoprazole sodium enteric coated tablets ranked first in three registration tests, among which two pantoprazole sodium enteric coated tablets were the consistency evaluation clinical trials, and the two registration varieties of amoxicillin capsule in top5 were all the consistency evaluation clinical trials, as shown in the figure below Note: this chart only lists the first five drug clinical registration varieties of this month, and there will be the same number of registration varieties not listed here later For more details, please click "read the original" to "drug intelligence data enterprise version of China clinical trial database" at the end of the article for inquiry PS1: the top rivaroxaban tablets are registered by the two bidding units of "Sanders (China) Pharmaceutical Co., Ltd." and "Hunan Jiudian Pharmaceutical Co., Ltd.", two of which are registered by "Sanders (China) Pharmaceutical Co., Ltd." and two of which are the bioequivalence tests of 10mg film coated tablets of rivaroxaban, which are taken orally once an empty stomach and after a meal respectively Proven PS2: pantoprazole sodium enteric coated tablets, which occupy the first place in the list, are also registered by "Hangzhou Kangenbei Pharmaceutical Co., Ltd." and "Shandong Yuxin Pharmaceutical Co., Ltd." two of them are registered by "Hangzhou Kangenbei Pharmaceutical Co., Ltd." and two of them are the bioequivalence test of pantoprazole sodium enteric coated tablets taken orally after meals and on an empty stomach Proven In October 2019, 27 of the 188 clinical trial registrations (11.24% increase on a month on month basis) publicized by CDE (20.59% decrease on a month on month basis) were clinical trial registrations for conformity assessment, among which "Hangzhou Kangenbei Pharmaceutical Co., Ltd., Zhongshan lienpu Pharmaceutical Co., Ltd and Hebei Medical University pharmaceutical factory" three bidding units registered two different research contents for one variety of their respective units See the table below for details Note: this table only lists 27 be tests for consistency evaluation There are 32 be tests for deemed consistency evaluation this month that can be queried in "enterprise version of pharmaceutical intelligence data - Chinese clinical trial database" According to the CDE announcement, by the end of October 2019, there are 4269 clinical trials of drugs in the completed state (134 clinical trials in the completed state only in October), of which 917 are consistency evaluation clinical trials (28 clinical trials in the completed state only in October); 4767 clinical trials of drugs are in the process of trial (including not yet recruited Among them, 397 were consistent evaluation clinical trials; 271 drug clinical trial sponsor units applied for active suspension of the trial, of which 15 were added in October See the figure below for details According to the analysis and statistics of pharmaceutical intelligence, in October 2019, the most concerned clinical trial bidding unit was Zhengda Tianqing Pharmaceutical Group Co., Ltd (ranked first in July), while Jiangsu Hengrui Pharmaceutical Co., Ltd., which ranked first in August and September, ranked second this month The bidding units of top 10 are listed here, as shown in the figure below.